Pfizer’s Read Criticizes Rebates Amid Changing Market Dynamics
Executive Summary
Pfizer CEO Ian Read suggested it might be time for a new solution that would allow the pharma industry to moderate pricing based on volume without relying on rebates, criticizing a practice he said has become “less helpful” in getting cost effective solutions to patients.
You may also be interested in...
Where Will It End? Lilly’s US Price Concessions Increase 30% In 2016
Eli Lilly recorded $7.69bn in rebates and discounts in the US in 2016 as pharmacy benefit managers demanded greater price concessions in crowded categories like diabetes.
Medicaid Reform And Rebates: State “Opt-Out” Proposed At Hearing
Medicaid rebates have been a fact of life in the pharmaceutical industry for 25 years. But the Affordable Care Act repeal-and-replace debate may open up the possibility of eliminating the mandatory rebates – and the requirement that all drugs be covered by the program.
US Drug Spending: Where Does All The Money Go?
PhRMA has released new data on where gross and net drug expenditure ends up along the pharmaceutical supply chain, which will support its position the debate over US drug pricing.